Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia

Pharmacogenomics Journal

Volumn 15, Issue 4, 2015, Pages 372-379

  Gregers, J ^a,b   Green, H ^a,c,d   Christensen, I J ^e   Dalhoff, K ^f   Schroeder, H ^g   Carlsen, N ^h   Rosthoej, S ⁱ   Lausen, B ^j   Schmiegelow, K ^j   Peterson, C ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b University Hospital in Copenhagen   (Denmark)

^c SCIENCE FOR LIFE LABORATORY   (Sweden)

^d National Board of Forensic Medicine   (Sweden)

^e FINSEN LABORATORY   (Denmark)

^f BISPEBJERG HOSPITAL   (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ AALBORG UNIVERSITY HOSPITAL   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DOXORUBICIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; VINCRISTINE; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; BONE MARROW DISEASES; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; DENMARK; GENETICS; GENOTYPE; HAPLOTYPE; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE; PRESCHOOL CHILD; RECURRENT DISEASE; RISK ASSESSMENT;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE MARROW DISEASES; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CHILD, PRESCHOOL; DENMARK; GENOTYPE; HAPLOTYPES; HUMANS; INFANT; MALE; METHOTREXATE; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84937815554     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.81     Document Type: Article

References (42)

1. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
2. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 371-382.
3. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
4. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30: 831-849.
5. Schmiegelow K, Forestier E, Kristinsson J, Soderhall S, Vettenranta K, Weinshilboum R et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009; 23: 557-564.
6. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S et al. The association of reduced folate carrier 80G4A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010; 115: 4671-4677.
7. Borst L, Wallerek S, Dalhoff K, Rasmussen KK, Wesenberg F, Wehner PS et al. The impact of CYP3A5∗3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur J Haematol 2011; 86: 477-483.
8. Borst L, Buchard A, Rosthoj S, Wesolowska A, Wehner PS, Wesenberg F et al. Gene dose effects of GSTM1, GSTT1 and GSTP1 polymorphisms on outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2012; 34: 38-42.
9. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011; 201: 261-283.
10. Schinkel AH, Wagenaar E, Mol CA, van DL. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524.
11. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 1996; 48: 1083-1089.
12. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-168.
13. Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003; 28: 203-228.
14. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174-1184.
15. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
16. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6: 610-617.
17. Kato T, Hamada A, Mori S, Saito H. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 2011; 27: 192-199.
18. Grabar PB, Rojko S, Logar D, Dolzan V. Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis 2010; 69: 931-932.
19. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267-2275.
20. Skarby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20: 1955-1962.
21. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006; 12: 854-859.
22. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 2008; 97: 2045-2048.
23. Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009; 113: 6077-6084.
24. Green H, Falk IJ, Lotfi K, Paul E, Hermansson M, Rosenquist R et al. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J 2010; 12: 111-118.
25. Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 2006; 95: 2767-2777.
26. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 2004; 310: 1199-1207.
27. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ. MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol 2009; 64: 183-188.
28. De Meyer M, Haufroid V, Elens L, Fusaro F, Patrono D, De PL et al. Donor age and ABCB1 1199G4A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. J Surg Res 2012; 178: 988-995.
29. Yang YL, Lin DT, Chang SK, Lin SR, Lin SW, Chiou RJ et al. Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 206-211.
30. Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D et al. Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev 2010; 11: 1063-1066.
31. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314-321.
32. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526-534.
33. Hoffmeyer S, Burk O, von RO, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
34. Jeannesson E, Albertini L, Siest G, Gomes AM, Ribeiro V, Aslanidis C et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol 2007; 21: 411-418.
35. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C4T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.
36. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
37. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105: 4752-4758.
38. Bolufer P, Collado M, Barragan E, Calasanz MJ, Colomer D, Tormo M et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007; 136: 590-596.
39. Stanulla M, Dynybil C, Bartels DB, Dordelmann M, Loning L, Claviez A et al. The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group. Haematologica 2007; 92: 1581-1582.
40. Guillem VM, Collado M, Terol MJ, Calasanz MJ, Esteve J, Gonzalez M et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 2007; 21: 1413-1422.
41. Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, Camitta B et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 2000; 14: 232-237.
42. Semsei AF, Erdelyi DJ, Ungvari I, Kamory E, Csokay B, Andrikovics H et al. Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res 2008; 32: 1214-1220.